AHA to HRSA: Implement 340B Drug Ceiling Price Rule Without Further Delay

AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers’ civil monetary penalties (CMPs) for violations of the ceiling price.

Key Resources

Related Resources

Advisory
HRSA Finalizes 340B Administrative Dispute Resolution Process
Member
Letter/Comment
AHA Responds to FDA's Proposed Regulation of Diagnostic Tests
Public
Letter/Comment
AHA Responds to Senate RFI on the SUSTAIN 340B Act Draft
Testimony
AHA Statement on "Evaluating Approaches to Diagnostic Test Regulation and the Impact of FDA’s Proposed Rule."
Guides/Reports
The 340B Drug Pricing Program
Letter/Comment
AHA Urges Congress to Provide Support to Help Minimize Further Fallout from Change Healthcare Attack
Public